USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products.
USANA Health Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$88.92|
|52 Week High||US$72.03|
|52 Week Low||US$107.85|
|1 Month Change||-5.96%|
|3 Month Change||-11.71%|
|1 Year Change||17.98%|
|3 Year Change||-25.43%|
|5 Year Change||30.15%|
|Change since IPO||14,492.00%|
Recent News & Updates
USANA Health Sciences (NYSE:USNA) Is Aiming To Keep Up Its Impressive Returns
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
|USNA||US Personal Products||US Market|
Return vs Industry: USNA underperformed the US Personal Products industry which returned 50.8% over the past year.
Return vs Market: USNA underperformed the US Market which returned 33.8% over the past year.
Stable Share Price: USNA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: USNA's weekly volatility (3%) has been stable over the past year.
About the Company
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups.
USANA Health Sciences Fundamentals Summary
|USNA fundamental statistics|
Is USNA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|USNA income statement (TTM)|
|Cost of Revenue||US$230.04m|
Last Reported Earnings
Jul 03, 2021
Next Earnings Date
|Earnings per share (EPS)||6.68|
|Net Profit Margin||11.09%|
How did USNA perform over the long term?See historical performance and comparison
Is USANA Health Sciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: USNA ($88.92) is trading below our estimate of fair value ($112.23)
Significantly Below Fair Value: USNA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: USNA is good value based on its PE Ratio (12.8x) compared to the US Personal Products industry average (16.8x).
PE vs Market: USNA is good value based on its PE Ratio (12.8x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: USNA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: USNA is overvalued based on its PB Ratio (4.3x) compared to the US Personal Products industry average (2.8x).
How is USANA Health Sciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: USNA's earnings are forecast to decline over the next 3 years (-3.5% per year).
Earnings vs Market: USNA's earnings are forecast to decline over the next 3 years (-3.5% per year).
High Growth Earnings: USNA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: USNA's revenue (0.3% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: USNA's revenue (0.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if USNA's Return on Equity is forecast to be high in 3 years time
How has USANA Health Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: USNA has high quality earnings.
Growing Profit Margin: USNA's current net profit margins (11.1%) are higher than last year (10.4%).
Past Earnings Growth Analysis
Earnings Trend: USNA's earnings have grown by 7.3% per year over the past 5 years.
Accelerating Growth: USNA's earnings growth over the past year (26.4%) exceeds its 5-year average (7.3% per year).
Earnings vs Industry: USNA earnings growth over the past year (26.4%) underperformed the Personal Products industry 54.7%.
Return on Equity
High ROE: USNA's Return on Equity (33.2%) is considered high.
How is USANA Health Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: USNA's short term assets ($381.5M) exceed its short term liabilities ($153.0M).
Long Term Liabilities: USNA's short term assets ($381.5M) exceed its long term liabilities ($19.8M).
Debt to Equity History and Analysis
Debt Level: USNA is debt free.
Reducing Debt: USNA has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.
Debt Coverage: USNA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: USNA has no debt, therefore coverage of interest payments is not a concern.
What is USANA Health Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate USNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate USNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if USNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if USNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of USNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Guest (58 yo)
Mr. Kevin G. Guest serves as Chairman of the Board of USANA Health Sciences, Inc. since May 1, 2020 and its Chief Executive Officer since November 23, 2016. Mr. Guest served as Co-Chief Executive Officer o...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD3.96M) is about average for companies of similar size in the US market ($USD3.69M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Experienced Management: USNA's management team is considered experienced (4.8 years average tenure).
Experienced Board: USNA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: USNA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
USANA Health Sciences, Inc.'s employee growth, exchange listings and data sources
- Name: USANA Health Sciences, Inc.
- Ticker: USNA
- Exchange: NYSE
- Founded: 1992
- Industry: Personal Products
- Sector: Household
- Market Cap: US$1.779b
- Shares outstanding: 20.01m
- Website: https://www.usana.com
Number of Employees
- USANA Health Sciences, Inc.
- 3838 West Parkway Boulevard
- Salt Lake City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:06|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.